Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus R-GemOx versus R-GemOx in relapsed or refractory diffuse large B-cell lymphoma in patients ineligible for high-dose therapy
ISRCTN11965217Phase 2Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and lymphoma (2 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Progression-free survival rate at 1 year. Started Jun 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)lymphoma
Beyond the preview
Go deeper on ISRCTN11965217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11965217.